Lalitha Super Specialty Hospital, Guntur, India; 2. Apollo Hospitals, Ahmedabad ... Sahajanand Medical Technologies Pvt. Ltd., Surat, India. Euro15A-POS136 ... Modified American College of Cardiology-American Heart. Association type B2 ...
5/16/2015
Clinical outcomes after implantation of bioabsorbable polymer coated sirolimus-eluting stent in multivessel stenting: 6-month follow-up data from the MUL…
Home / Archives / Abstracts EuroPCR 2015 / Clinical outcomes after implantation of bioabsorbable polymer coated sirolimus-eluting stent … /
Clinical outcomes after implantation of bioabsorbable polymer coated sirolimuseluting stent in multivessel stenting: 6-month follow-up data from the MULTIDOS study
Polavarapu R.S.1, Prajapati J.2, Thakkar K.3, Raheem A.4, Pamidimukkala V.1, Polavarapu A.1, Polavarapu N.1, Rachaputi M.B.R.1, Noronha M.1, Khambhati B.5, Thakkar A.5 1. Lalitha Super Specialty Hospital, Guntur, India; 2. Apollo Hospitals, Ahmedabad, India; 3. Lions Sterling Super Specialty Hospital, Mehsana, India; 4. Yashfeen Cardiac Hospital, Navsari, India; 5. Sahajanand Medical Technologies Pvt. Ltd., Surat, India Euro15A-POS136
Coronary interventions Clinical outcomes after implantation of bioabsorbable polymer coated sirolimus-eluting stent in multivessel stenting: 6-month follow-up data from the MULTIDOS study Polavarapu R.S., Prajapati J., Thakkar K., Raheem A., Pamidimukkala V., Polavarapu A., Polavarapu N., Rachaputi M.B.R., Noronha M., Khambhati B., Thakkar A. 1. Lalitha Super Specialty Hospital, Guntur, India; 2. Apollo Hospitals, Ahmedabad, India; 3. Lions Sterling Super Specialty Hospital, Mehsana, India; 4. Yashfeen Cardiac Hospital, Navsari, India; 5. Sahajanand Medical Technologies Pvt. Ltd., Surat, India Aims: The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. Drug-eluting stents (DES), with permanent polymer, are related to potential risk because of inflammatory reaction and delayed healing. In this point, bioabsorbable polymer coated sirolimus-eluting stent (SES) could enhance clinical outcomes. The aim of this study was to examine the incidence of clinical outcomes after utilisation of the Indolimus, bioabsorbable polymer coated SES (Sahajanand Medical Technologies Pvt. Ltd, India), in multivessel coronary stenting in an unselected patient population. Methods and results: From April 2012 to June 2014, a total of 151 patients, exclusively treated with Indolimus SES in multivessel (≥2 vessels), were examined in the non-randomised, observational, multi-centre MULTIDOS study. We analysed 6-month clinical outcomes [major adverse cardiac events (MACE); defined as composite of cardiac death, myocardial infarction (MI), target lesion revascularisation (TLR) and target vessel revascularisation (TVR)], as a primary end point, after multi-vessel stent implantation. The mean age was 53.7±10.7 years; male gender represented 108 (71.5%) patients; and 58 (38.4%) and 56 (37.1%) of them were diabetic and hypertensive patients, respectively. The most prevalent clinical presentation was unstable angina in 44 (29.1%) patients, followed by stable angina in 18 (11.9%) patients. Modified American College of Cardiology-American Heart Association type B2 and C lesions accounted for 121 (40.1%) lesions. A total of 314 Indolimus stents (two, three and four stents in 92.7%, 6.6% and 0.7% of patients, respectively) were implanted at index procedure (2.1 stents per patients) with an average diameter and total stent length of 3.1±0.4 mm and 26.8±9.2 mm, respectively. Clinical follow-up was completed in 147 (97.4%) patients at 6-month. The primary endpoint, a composite of MACE at 6month follow-up, occurred in 4 (2.7%) patients, consisting of 1 (0.7%) cardiac death, 2 (1.3%) MI, 1 (0.7%) TLR and 0 (0%) TVR. There was no stent thrombosis during 6 months of follow-up. Conclusions: The present study describes that Indolimus SES implantation is a safe and effective treatment in multivessel coronary artery disease, showing low rates of major adverse cardiac events at 6-month follow-up. Long-term follow-up is warranted to discriminate clinical safety and efficacy.
Previous
Next
Share this article: Facebook
Tweet
LinkedIn
Google +
Email
http://www.pcronline.com/eurointervention/AbstractsEuroPCR2015/POS136/
1/1
